Catalyst’s intellectual property is a method of treating Tourette Syndrome using GABA aminotransferase inhibitor drugs, including CPP-109 and CPP-115.
The method increases presynaptically stored GABA, and enhance GABA signaling in the striatal-thalamo-cortical tracts involved in habit formation and motor control.
Catalyst CEO Patrick McEnany said the use of CPP-109 and CPP-115 in the treatment of Tourette Syndrome may provide them with significant CNS expansion opportunities while addressing an important medical need.